Utilization of ctDNA Assays Could Determine Benefit of Adjuvant Chemotherapy in Resectable CRC
The use of ctDNA assays may help identify patients with colorectal cancer who could benefit from adjuvant chemotherapy. The use of circulating tumor (ct)DNA assays may help identify patients with colorectal cancer who could benefit from adjuvant chemotherapy, according to data from the observational GALAXY trial (UMIN000039205), which were presented at...
www.onclive.com
Comments / 0